Cephalogics Announces Results of in vivo Studies that Demonstrate the Ability of its Compact Perfusion Imaging System to Iden...
September 19 2016 - 08:00AM
Business Wire
- These in vivo studies demonstrate
the ability of Cephalogics’ portable brain imaging system to
noninvasively measure the impact of cerebrovascular occlusions and
cerebral vasoconstriction.
- These study results were presented
at the 2016 Neurocritical Care Society meeting in National Harbor,
MD, and introduced the capabilities of the Cephalogics brain
perfusion imaging system to the medical community.
Cephalogics announced study results from two in vivo studies
that demonstrated the imaging capability of the company’s compact
portable non-invasive brain perfusion imaging system to identify
and track perfusion deficits in humans and pigs. The first study
demonstrated the system’s ability to detect and measure perfusion
deficits caused by vasoconstriction in human and porcine subjects
induced by hyperventilation. The second study was performed at
Tufts Medical Center Animal Lab and demonstrated the ability to
measure perfusion deficits induced by occluding cerebral vessels in
a healthy porcine brain, which were confirmed by angiography.
“This is an exciting development for a new non-invasive optical
technology that would be very useful for optimizing clinical
management of cerebral perfusion in the Neurocritical Care
setting,” said Adel Malek, MD, PhD, Professor of Neurosurgery at
Tufts University School of Medicine and Chief of Neurovascular
Surgery at Tufts Medical Center in Boston.
Cephalogics presented two abstracts from these recent studies at
the 14th Annual Meeting of the Neurocritical Care Society (NCS)
September 15-18 in National Harbor, Maryland. These presentations
showcased the capabilities of the Cephalogics system to the medical
community through demonstrations with clinical applications. The
system is designed to provide continuous bedside brain perfusion
imaging of patients suffering from stroke or severe traumatic brain
injury, giving clinicians access to information that can help them
quickly identify and treat perfusion deficits in order to avoid
ischemia and associated adverse outcomes.
“Sharing these exciting in vivo results with clinicians at the
Neurocritical Care Society meeting marks an important step forward
for Cephalogics,” said Jeff Caputo, General Manager of Cephalogics.
“These results bring us closer to achieving our mission to give
clinicians the accurate, actionable information they need to
quickly detect perfusion deficits and facilitate early
interventions.”
Cephalogics’ imaging system utilizes Diffuse Optical Tomography
(DOT) to provide bedside brain perfusion imaging of multiple large
cerebrovascular regions within a patient’s brain. The system’s
sensors consist of compact, high-density arrays with numerous near
infrared (NIR) light sources and detectors to provide hundreds of
simultaneous spatially resolved measurements per region. These
measurements are then processed to produce regional maps of the
oxygen saturation in cerebral tissue. Each sensor array covers a
cerebrovascular area of approximately 2”x4”.
“The oxygenation maps presented in these studies showcase our
ability to measure induced cerebral perfusion deficits in vivo,”
said Bertan Hallacoglu, PhD, Research and Development Scientist at
Cephalogics. “We are excited to continue testing our methods in
vivo and look forward to sharing results from patient testing in
the future.”
Stroke is the third leading cause of death in the U.S., and
along with severe traumatic brain injuries results in billions of
dollars spent on healthcare each year. Current methods used to
monitor patients and assess oxygen saturation in the brain are
typically invasive, focal or require transport from a patient’s
room. This inability to quickly assess brain perfusion at the
bedside can raise the risk of ischemia and associated adverse
outcomes in brain-injured patients. Cephalogics aims to provide
clinicians with a compact, portable, and easy-to-use brain
perfusion imaging system to help avoid ischemia and its associated
adverse outcomes.
For more information about Cephalogics, visit
www.cephalogics.com.
About Cephalogics
Cephalogics is developing a non-invasive, portable brain
perfusion imaging system that is designed to provide clinicians
with critical information for detecting and treating perfusion
deficits and avoiding ischemia in brain-injured patients. The
system is designed to "see” the brain through hair, skin and skull,
mapping oxygen saturation in the brain and help to facilitate early
interventions, improve outcomes and reduce healthcare costs.
Cephalogics' system utilizes Diffuse Optical Tomography (DOT) to
provide bedside imaging of multiple cerebrovascular regions within
a patient's brain. The system's sensors consist of compact,
high-density arrays with numerous near infrared (NIR) laser light
sources and detectors to provide hundreds of simultaneous spatially
resolved measurements per region. These measurements are processed
in real time to produce regional maps of the oxygen saturation in
cerebral tissue. Each sensor array covers a cerebrovascular area of
approximately 40cm2. Cephalogics is developing and commercializing
an imaging system based on technology invented by Dr. Joseph P.
Culver, a Professor at Washington University and a leading
researcher in the field of Diffuse Optical Tomography. More
information about the company can be found
at www.cephalogics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160919005371/en/
ArcPoint Strategic CommunicationsChristine Dunn, 617-484-1660,
x101cdunn@arcpointstrategy.com
Allied Minds (LSE:ALM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Allied Minds (LSE:ALM)
Historical Stock Chart
From Mar 2023 to Mar 2024